BiotechTube

Secukinumab + Secukinumab and Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Axial Psoratic Arthritis

Conditions

Axial Psoratic Arthritis

Trial Timeline

Oct 3, 2016 → Jun 26, 2019

NCT ID
NCT02721966

About Secukinumab + Secukinumab and Placebo

Secukinumab + Secukinumab and Placebo is a phase 3 stage product being developed by Novartis for Axial Psoratic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02721966. Target conditions include Axial Psoratic Arthritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02721966Phase 3Completed

Competing Products

20 competing products in Axial Psoratic Arthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
Brodalumab + PlaceboKyowa KirinPhase 3
77
Ixekizumab + PlaceboEli LillyPhase 3
77
Ixekizumab + PlaceboEli LillyPhase 3
77
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
77
SHR-1314Jiangsu Hengrui MedicinePhase 1
33
UpadacitinibAbbViePre-clinical
23
AdalimumabAbbVieApproved
85
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
77
adalimumab + PlaceboAbbViePhase 3
77
TreatmentMerckPre-clinical
23
GolimumabMerckPhase 3
77
Tulisokibart + PlaceboMerckPhase 2
52
Secukinumab 150 milligram [Cosentyx]NovartisApproved
85
secukinumabNovartisPre-clinical
23
Secukinumab + PlaceboNovartisPhase 3
77
Secukinumab + Placebo + SecukinumabNovartisApproved
85
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
77
Brodalumab 210 mg + PlaceboAmgenPhase 2
51
Etanercept 25mg + SulfasalazinePfizerPhase 2
51

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85